spot_img
Tuesday, June 21, 2022
More
    HomeHealthUCB to buy Zogenix, maker of rare epilepsy treatment, for $1.9 billion

    UCB to buy Zogenix, maker of rare epilepsy treatment, for $1.9 billion

    -



    Belgian drug maker UCB stated Wednesday that it’s increasing its portfolio of epilepsy therapies by buying Zogenix, a U.S.-based biotech with an accredited drug for uncommon childhood seizures, for as a lot as $1.9 billion.

    Underneath the phrases of the deal, Zogenix can be bought for $26 per share, or 66% greater than Tuesday’s closing value. UCB has additionally agreed to pay Zogenix shareholders an added cost equal to $2 per share, contingent on the corporate’s drug, known as Fintepla, profitable European approval by the tip of 2023.

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,356FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts